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ABSTRACT   
 
Mutations in CHCHD2 and CHCHD10 were recently reported in a broad spectrum of neurodegenerative 
diseases, e.g. Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia or mitochondrial 
myopathy (MM). The aim of the study was to evaluate the prevalence of CHCHD2 and CHCHD10 mutations 
in Italian MM patients without mitochondrial DNA mutations. The coding regions of CHCHD2 and 
CHCHD10 were sequenced in 62 MM patients. None of the patients showed CHCHD2 mutations, whereas 
one sporadic MM patient carried a homozygous Pro96Thr substitution in CHCHD10. Muscle biopsy of this 
patient showed intracellular glycogen accumulation with cytochrome c oxidase negative and ragged red 
fibers. Our study suggests that the homozygous Pro96Thr mutation in CHCHD10 might be pathogenic, but 
does not support a major role for CHCHD2 in MM pathogenesis. 
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Introduction  
Mitochondrial myopathies (MM) can be caused by mutations in genes encoded by nuclear or mitochondrial 
DNA (mtDNA). A new family of mitochondrial (nuclear) proteins with a CHCH-domain and mitochondrial 
targeting sequence includes CHCHD2 and CHCHD10 that regulate oxidative phosphorylation, cytochrome c 
oxidase (COX) activity, and cristae morphology. CHCHD10 mutations were recently reported in patients 
with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) (Bannwarth et al., 2014; 
Zhang et al., 2015). Intriguingly, patients from a French pedigree carrying a compound heterozygous 
CHCHD10 cis-mutation (Arg15Ser/Gly58Arg) presented with a complex phenotype, including cerebellar 
ataxia, parkinsonism, MM, ALS or ALS/FTD (Ajroud-Driss et al., 2015). The ALS-causing Arg15Leu 
mutation destabilizes the CHCHD10 protein, leading to impaired cellular respiration and an increase in the 
steady-state level of CHCHD2 (Straub et al., 2017). Coding mutations in CHCHD2 were reported in 
Japanese patients with an autosomal dominant Parkinson’s disease (PD) (Funayama et al., 2015). CHCHD2 
variants (rs10043, rs142444896) were associated with sporadic PD, but not in Caucasians (Rubino et al., 
2017). Here, we conducted a mutation analysis of CHCHD2 and CHCHD10 in Italian MM patients. 
 
Methods  
The exons of CHCHD2 and CHCHD10 were analysed by Sanger sequencing in 62 MM patients without 
mutations in mtDNA. The frequencies of the variants were compared to public databases. Histological study 
included hematoxylin/eosin and Gomori modified trichrome staining, as well as COX and succinate 
dehydrogenase (SDH) activity. Electron microscopy results were also available.  
 
Results 
In CHCHD2, we detected only a non-coding variant (rs10043, c.-9 T>G) in the 5’ UTR (previously 
implicated in PD) with a minor allele frequency (MAF) of 0.289, which is similar to that reported in the 
1000 Genomes database for the European population (MAF=0.223; p=0.197). Sequencing of CHCHD10 
showed a synonymous variant (rs111527940; c.234 G>A) in one patient, which is similar to the frequency in 
the European population (1000 Genomes). Furthermore, we identified a homozygous Pro96Thr substitution 
in exon 3 (rs111677724; c.307 C>A) (Supplemental Fig. 1). The frequency of rs111677724 in our dataset 
(MAF=0.016) was significantly higher than in the European population from 1000 Genomes database 
(MAF=0.001; p=0.012) or the Exome Aggregation Consortium database (MAF=0.006), where only one 
homozygote was observed among 6013 individuals of European origin. This mutation is predicted to be 
deleterious by SIFT or possibly damaging by Polyphen 2. 
Clinical information of the Pro96Thr carrier is available in the supplemental material. A muscle biopsy 
showed a typical pattern of MM as dystrophic features, several ragged red fibers, glycogen accumulation 
and 40% COX negative fibers (Supplemental Fig. 2) with a medium quantity of blood lactate (<4 mM). 
Electron microscopy showed aggregates of abnormal mitochondria with paracrystalline inclusions.  
 
Discussion 
In our MM cohort, we did not find any novel pathogenic CHCHD2 mutations or any of the rare CHCHD2 
mutations previously reported in different neurological disorders. However, the analysis of CHCHD10 
revealed one MM patient with a homozygous Pro96Thr substitution in exon 3, which is 40 amino acids 
away from exon 2 (a hotspot for pathogenic mutations in CHCHD10) (Straub et al., 2017). This patient 
showed several ragged-red and COX-negative fibers associated with mitochondrial deletions at muscle 
biopsy, similar to previous findings in CHCHD10 patients. The homozygous Pro96Thr mutation was 
previously described as pathogenic in three ALS patients of European origin (Dols-Icardo et al., 2015; 
Teyssou et al., 2016).  
In conclusion, our data suggest that the homozygous Pro96Thr mutation in CHCHD10 might be related to 
MM risk in some Italian patients, but do not support a major role of CHCHD2 in MM pathogenesis. The 
limitation of the current study is the modest MM cohort; however, the patients were investigated with 
multiple methodologies including morphological, biochemical and molecular studies of muscle biopsies. 
Further investigation is needed to analyze the role of CHCHD2 and CHCHD10 in different populations. 
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